Frye MA

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, 55905, USA.

9 papers · ORCID

ArticleKetamine

Modulation of GABA and glutamate by ketamine in depression: A systematic review and meta-analysis of magnetic resonance spectroscopy studies.

Singh B, Ali HM, Miola A +8

Europe PMC2026
ArticleKetamine

Metabolomic correlates of intravenous racemic ketamine in treatment-resistant major depressive disorder: the Bio-K/NNDC multicenter trial.

Singh B, MahmoudianDehkordi S, Vande Voort JL +9

Europe PMC2026
ArticleKetamine

Next-Step Treatment Options for Treatment-Resistant Depression: Insights From the Mayo Clinic Depression Center Panel.

Marques MG, Özerdem A, Kung S +10

Europe PMC2026
ArticleKetamine

Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis.

Elmosalamy A, Tarikogullari I, Patarroyo-Rodriguez L +5

Europe PMC2025
ArticleKetamine

Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression: A 6-Month Mirror-Image Study.

Patarroyo-Rodriguez L, Pazdernik VK, Vande Voort JL +3

Europe PMC2025
ArticleKetamine

Bipolar disorder.

Singh B, Swartz HA, Cuellar-Barboza AB +7

Europe PMC2025
ArticleKetamine

Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial.

Penaluna BK, Vande Voort JL, Bobo WV +7

Europe PMC2025
ArticleKetamine

Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine.

Singh B, Vande Voort JL, Pazdernik VK +2

Europe PMC2024
ArticleKetamine

Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.

Singh B, Kung S, Pazdernik V +5

Europe PMC2023